Breaking Down SG&A Expenses: AstraZeneca PLC vs Biogen Inc.

A Comparative Analysis of SG&A Expenses: AstraZeneca PLC vs Biogen Inc.

In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, AstraZeneca PLC and Biogen Inc. have demonstrated distinct approaches to managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, AstraZeneca's SG&A expenses have shown a significant upward trend, peaking in 2022 with a 90% increase from 2016. In contrast, Biogen Inc. maintained a more stable expenditure pattern, with a modest 32% rise over the same period. This divergence highlights AstraZeneca's aggressive investment in marketing and administrative capabilities, possibly reflecting its strategic focus on expanding market share. Meanwhile, Biogen's steady approach suggests a focus on operational efficiency. As these companies navigate the competitive landscape, their financial strategies offer valuable insights into their long-term visions.